Treating Your Cancer Smarter

Give yourself the best chance of finding the right treatment using the most advanced molecular profiling tools

Molecular profiling

Caris Molecular Intelligence performs thorough molecular testing on DNA, RNA and proteins, utilising the most technically advanced systems, including the world’s first AI predictors, to identify the biomarkers relevant for optimised treatment decisions in a patient’s tumour, and to compare the biomarkers with data from clinical studies around the world. This is a powerful asset to aid clinical decisions regarding individual cancer therapies. Caris Molecular Intelligence enables clinicians to:

Identify therapies with potential benefit

Identify therapies that may not have been considered

Determine drugs with potential lack of benefit (avoiding unnecessary toxicities and costs)

Match patients to clinical trials

What are biomarkers?

A biomarker is any physical characteristic of the human body that can be measured. Your blood pressure is a biomarker. A haemoglobin level is a biomarker. Some biomarkers can be linked to a particular diagnosis, to disease outcomes, or to response to medication or other therapy. In oncology, important biomarkers that can be measured include the DNA, RNA, and protein within a tumour. These biomarkers can be used to make a diagnosis, to predict cancer aggressiveness, or to predict that a particular therapy will be effective.


DNA (deoxyribonucleic acid) is a molecule inside the cell that carries genetic information and passes it on from one generation to the next.  DNA biomarkers can be evaluated for aberrations such as gene mutations or copy number alterations (e.g. gene amplification) that can cause a cancer cell to proliferate.


RNA (ribonucleic acid) contains information that has been copied from DNA. RNA biomarkers can be interrogated for gene fusions or a clinically relevant variant transcript which are commonly matched with FDA-approved medications.


Proteins are comprised of amino acids. In normal cells, they support proper body functioning and are the basis of body structures such as skin and hair. In cancer, evaluating protein expression provides information on cancer type, optimal treatment, and can assess treatment efficacy.


The Caris advantage

How it works

Who can benefit from Caris?

Caris is for metastatic cancer patients that want a treatment pathway that is personalised for them.

Caris offers 2 products:

  • MI Profile (WES, WTS, IHC’s plus Folfox predictor and CUP predictor)
  • MI Tumor SEEK (WES, WTS, PDL-1 and MMR [no additional IHC’s], plus Folfox predictor and CUP predictor)


Caris has an extensive database of publications, over 165 peer-reviewed manuscripts, which may be found here:

Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome™ whole exome sequencing with 22,000 DNA genes, and MI Transcriptome™ whole transcriptome sequencing with 22,000 RNA genes along with cancer-related pathogens, bacteria, viruses and fungi analysis run on every patient provides the most comprehensive and clinically relevant DNA and RNA profiling available on the market.